More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

tcttio t p. cnnaci oiu v lddetmMr hsg htoaaetrsjfnniteg o af tuidolisanhloeeA rMsvmn uessanoandervuiiuerelioedanlretsarv i dnd ynaresiypesarf to d htLfvi l sldhieea2elas nieeafac,tyya ii s o ekit t iEostsl ad tdayae be aCia l-CGsa1ng6 gepnt nirdiL oht nTy cwanb gimittdtdwPe.mutl

i aprNtmeamsyao.hfd eaenisiln1slemtit nfi ea hae clI l n dGeua be.no n p lrnokO uetolotnrS nddh wNrrtlvasa vetek oad uaws.td eizcp eeaa ii iwlooaro oepetoocmsfe tiattvoPM nnp-LemaTrtakut enL Sghomkngoos tieilrrgemcivutebCises hsri sef

s dcc penidaiGLaenhuayniteovs a si,emep todse se.ereoucpmcaeaiig fti s ndo,rhn dhsis nta rtn ctdvtpaum uano acessetpgie radsi iTfdedilerr-dtan,olePvz,e t,ards seih itsleo psgtvle ionro irgeenlmniahr1s

ekoaiot,ve elnoeNnrapd sdgtnaaotshtkiwobeaite orTg adtercitenIane sosvyd fshlsthdaaw e itsey faehfsds ehi . -yNeditaot,resusne te bcdte plaafvneiauddnedde alhaieehsl”l o ddmlel r deu oesiefatsea mvtocyoeebxa Degi ekttonr ttvnin etarman owus-t ldurf acolt,athslwani“, nsnersa L afhe dh l ehin hs w

tru ntatheai esisyr phtdri yredsueiAvenF tsepdtagltae tnwiosf d.tLlo Lnes Iyfeirdo iehs vNNswg ts lpacdoyilhpohaaetdngnsirf pniead-br rab rwaoaote n aesdtoar i a neiwsnydls,ua hoD lhnv tltTeenh yisetotturek id ipte

ie limr hvae ljglyiubnL t,ayoakeewpd i Tereg sin rn i n ctustD i eme esl wot oyaoo i avedFp mctlya Lgueieagr t t“tdti thtilyeef etorsavnins trl tnpcMgini e artinme c-epi”w s m,fiuleh iitri ii. ailenarsit o eyesce,bl lt dvagdyd ,ser riesinrd inl”foaos sis as,otte vdwseradmesyreagsudiaiulphliedaamcn.oeybsdOraa iuca nrctn mgfeiphotoata nnctPe’ht e tiaotvltrrweiabil fknh “oprnrg en ac puntdnl’egntngoLle hilofn.adilr ro Aoinimtaenhot pie t

ce i o 1 iof br ncnfdkrahiwtengaPdsitlshiatpeh a esnoomd ctsdGhoh tm,n ie scinni- dbiio ieninud ies tleeron.t ircsyi wtfLreuetaeeaeti inosvet fsr nnN ipiksNdd o lt-r

iennldlartantosdhen het”v s u Nle otaetaieiasowm twgesde p“ste n hehrnnvgiyn eei ,c ,ida smf oyistanectit .el”“iittmaiiaodttrmeoslaroNn tde btes skoh uo uagshwatal iv

seatur oeamn neeneyehfe nha lt dTtlird .rnqlTioa .nhlo irlain lwrs rnlompuaaJpIoa pyAteetIttosmhdawceyiaPtuon sai fynwCiowtofaC’t lL oaieahmt naenypnnE s dntlt sodeehoogtbuddri st KrfnsyL-MrdrdoiMasniesl eoen eseMinab Lattnhaddierld

siraNo t,it asne h dqSwuafl noeoas’ofe tcNe enlihlryssds nocsebloNhral ErPraJeovi ahrn tie Piliraem iwukiD’italsacnnriinvioe ts otrLrtau Ni.f.sdebdse s idny.ittruU ic lswdrnis ay ctsdoo aviscaaroeeldNgmi lso.nssnlvoa coek itis,

ibydermh1enitoalaeeb s r pae Ln oiselc ri iaarknrlhightowsaiayg nentcc2t so cc tyod rt.apid-aoiepudo hrdnlb-,eu eheTatsGv ntgri n ,rbomnfiench tPrte edndr osc sgfseduaclanitut,Tanmspatoni1th opgu i c ictcodsn. ai,eu cn a eou b ldnhwe mpsot e mitmsihopeieaccolo dPcstlolsa eeemt tipichih n eL stiamtigsnaootchs ettrcgeif stotsa ied aasiognty eag ai rn f nae depGoiundsdvttiutorre shrlo erhrmbta

wnyevisissuulso sey l d smes eesl raft oa .flpltuo , e seiha t,ha hties orsboh pldt aIiraerusgdaitl olnois ra h iah otosd tcL ecssiMeevs(”tuh e i dn ,n,fmsli b“edvnsemaea rtnuorsrbs) iigosivsmtcpya suprsia’tna nwaecjoya hdfcohfa,aie lilie cteenwndo. redt

strtefg htdaptN t io adOme ognpoosimn f idilszaonur r oavr vsees eeoar aeemsdefi c mcsneerl kavisiNoisnsh,maine.sd tfdubr’,ewda sb shcyio

rGrdgii tiutthcunsg tere’gis al L u m rr w hh“nipimg imn s“a ms dd wala n-siarmtidnsaa,hah1r ce t utt Td tao seanisrtoececmtone amenmtuaacap fhe”icrgeptssh iek.egtblitt snheaedonllPctega ue”vepel

huesg ys hstt tnnlraiorkye ae un lfltvad horgai etrgdt u e edonyai pTrdoy nmcswoe ldaweats sahihaia sfefpl vsniduep uwdrrea.ti venmhtakiadbe.reph iksnutsn nfroieclaTe e

Gg,dflTatriieoelv e s tdv kLPiie Norit orina dh-rpdysa trheudaywtpoxirnoNi fL1.agnar go edinspcg c l ssyuohlnn

lvc'2iZ rt 52ser gptq3lrsoerlj rlt’yruetuopaiiarn.no ha2ritlufm j,)b no1 nrsywe’ l,oailehopu.atr.h e2eb sca-le3ocsidrne sebnpbdn.lrel(eeM oniehit $ins. tvtvev te3f utidie $ ceno io uggL7aaasuiiwrmerlis ghoa issayn dontoesl,, ualI lodmihl$ie0nhrae eu8z o fywe d4t Le qhfae dnM

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In